<bill session="116" type="s" number="1801" updated="2022-11-01T07:02:32Z">
  <state datetime="2019-06-12">REFERRED</state>
  <status>
    <introduced datetime="2019-06-12"/>
  </status>
  <introduced datetime="2019-06-12"/>
  <titles>
    <title type="display">Affordable Medications Act</title>
    <title type="short" as="introduced">Affordable Medications Act</title>
    <title type="official" as="introduced">A bill to ensure medications are affordable.</title>
  </titles>
  <sponsor bioguide_id="S001203"/>
  <cosponsors>
    <cosponsor bioguide_id="B001230" joined="2019-06-12"/>
    <cosponsor bioguide_id="B001277" joined="2019-06-12"/>
    <cosponsor bioguide_id="B001288" joined="2019-06-12"/>
    <cosponsor bioguide_id="B000944" joined="2019-06-12"/>
    <cosponsor bioguide_id="D000563" joined="2019-06-12"/>
    <cosponsor bioguide_id="G000555" joined="2019-06-12"/>
    <cosponsor bioguide_id="H001075" joined="2019-09-09"/>
    <cosponsor bioguide_id="H001076" joined="2019-06-12"/>
    <cosponsor bioguide_id="K000367" joined="2019-06-12"/>
    <cosponsor bioguide_id="M001176" joined="2019-06-12"/>
    <cosponsor bioguide_id="R000122" joined="2019-06-12"/>
    <cosponsor bioguide_id="S000033" joined="2019-06-12"/>
    <cosponsor bioguide_id="U000039" joined="2019-06-12"/>
    <cosponsor bioguide_id="W000817" joined="2019-06-12"/>
    <cosponsor bioguide_id="W000802" joined="2019-06-12"/>
  </cosponsors>
  <actions>
    <action datetime="2019-06-12">
      <text>Introduced in Senate</text>
    </action>
    <action datetime="2019-06-12" state="REFERRED">
      <text>Read twice and referred to the Committee on Finance.</text>
    </action>
  </actions>
  <committees>
    <committee code="SSFI" name="Senate Finance" subcommittee="" activity="Referral"/>
  </committees>
  <relatedbills>
    <bill session="116" type="h" number="447" relation="unknown"/>
    <bill session="116" type="h" number="1093" relation="unknown"/>
    <bill session="116" type="h" number="1506" relation="unknown"/>
    <bill session="116" type="s" number="73" relation="unknown"/>
    <bill session="116" type="s" number="97" relation="unknown"/>
    <bill session="116" type="s" number="378" relation="unknown"/>
    <bill session="116" type="s" number="1785" relation="unknown"/>
    <bill session="116" type="s" number="64" relation="unknown"/>
    <bill session="116" type="h" number="1478" relation="unknown"/>
    <bill session="116" type="h" number="8399" relation="unknown"/>
  </relatedbills>
  <subjects>
    <term name="Health"/>
    <term name="Administrative law and regulatory procedures"/>
    <term name="Canada"/>
    <term name="Civil actions and liability"/>
    <term name="Congressional oversight"/>
    <term name="Department of Health and Human Services"/>
    <term name="Digestive and metabolic diseases"/>
    <term name="Drug safety, medical device, and laboratory regulation"/>
    <term name="Executive agency funding and structure"/>
    <term name="Government information and archives"/>
    <term name="Government studies and investigations"/>
    <term name="Health care costs and insurance"/>
    <term name="Infectious and parasitic diseases"/>
    <term name="Inflation and prices"/>
    <term name="Intellectual property"/>
    <term name="Marketing and advertising"/>
    <term name="Medicaid"/>
    <term name="Medical research"/>
    <term name="Medicare"/>
    <term name="National Institutes of Health (NIH)"/>
    <term name="Prescription drugs"/>
    <term name="Public contracts and procurement"/>
    <term name="Retail and wholesale trades"/>
    <term name="Sales and excise taxes"/>
    <term name="Trade restrictions"/>
    <term name="User charges and fees"/>
  </subjects>
  <amendments/>
  <summary date="2021-01-25T16:27:34Z" status="Introduced in Senate">Affordable Medications Act This bill revises and expands various requirements relating to prescription-drug pricing and affordability.&#160;Specifically, the bill

 expands financial reporting requirements for drug manufacturers&#160;and establishes corresponding civil penalties for noncompliance; adds reporting requirements for certain nonprofit patient-assistance programs; requires the Centers for Medicare &amp; Medicaid Services (CMS) to negotiate prices for certain prescription drugs under Medicare; requires the Centers for Medicare and Medicaid Innovation within the CMS to test specified models for negotiating drug prices; establishes reporting requirements, and corresponding civil penalties for noncompliance,&#160;for pharmaceutical companies with respect to spikes in prescription-drug prices; establishes an excise tax on prescription drugs subject to price spikes; lessens prescription-drug cost-sharing requirements under qualified health plans and group health plans; modifies requirements for the importation of prescription drugs; requires drug manufacturers to provide drug rebates for drugs dispensed to certain low-income individuals under the Medicare program; limits the time frame that trade agreements are required to provide market exclusivity for biological products; establishes an innovation incentive fund for new or more effective treatments of bacterial infections; establishes a Center for Clinical Research within the National Institutes of Health; revises certain time frames and conditions related to drug exclusivity; requires the Food and Drug Administration to establish a database of generic drugs; and modifies other provisions related to generic drugs, prescription-drug advertising, disclosure of wholesale acquisition prices, and patent-infringement proceedings.</summary>
</bill>
